Amgen Bolsters its CV Pipeline with Arrowhead’s RNA Interference Therapies
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)
Published: 19 Oct-2016
DOI: 10.3833/pdr.v2016.i10.2202 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to build its cardiovascular pipeline, Amgen has entered into two agreements with Arrowhead Pharmaceuticals to develop and commercialise RNA interference (RNAi) therapies for cardiovascular disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS